Elliot Marseille is a leading expert on the economics of the emerging psychedelic-assisted therapies. He is the founding Director of UC Berkeley's Collaborative for the Economics of Psychedelics (CEP), a network of health economists and health services researchers dedicated to realizing the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, CEP seeks to enhance the efficiency, and increase access to these promising therapies. Among CEP’s current projects are analyses of the economics of psilocybin-assisted therapy for major depression, psilocybin for tobacco cessation, ibogaine for opioid use disorder and extended analyses of the economics of MDMA-assisted therapy for PTSD.
Dr Marseille has over 35 years of experience in senior public health management and research positions. In addition to the economics of psychedelic therapies, he has published widely on the economics of global health interventions, especially for HIV/AIDS.